Unraveling the Mechanism of Action of Bispecific T-Cell Engagers in B-Cell Acute Lymphoblastic Leukemia Using Advanced Single-Cell Multiomics

Blinatumoab公司 CD19 T细胞 B细胞 免疫学 医学 血液学 CD8型 免疫系统 癌症研究 抗体
作者
Anna Schnaiderman Shapiro,Eitan Winter,Yakir Moshe,Yonatan Katzenelenbogen,Diego Adhemar Jaitin,Mor Zada,Oren Barboy,Ido Yofe,Paulina Chalan,See Phan,Amir Giladi,Michael Shapiro,Renana Robinson,Eitan Kugler,Ofir Wolach,Irit Avivi Mazza,Ido Amit
出处
期刊:Blood [Elsevier BV]
卷期号:142 (Supplement 1): 599-599
标识
DOI:10.1182/blood-2023-188930
摘要

Background Bispecific T-cell engagers (BiTEs) stimulate T lymphocytes proximate to tumor cells, inducing T-cell stimulation and tumor killing. Blinatumomab, an anti CD3-CD19, was the first to be approved with overall response rates of up to 80% in refractory B-cell Acute Lymphoblastic Leukemia (B-ALL). To overcome resistance and to develop next-generation BiTEs, we need to build on blinatumomab's success and better understand BiTEs mode of action and interaction with the tumor microenvironment (TME). Here, we apply advanced multiomics to examine blinatumomab's activation signatures and the sustained dynamics in the tumor and bone marrow (BM) immune TME. Methods Physically interacting Cells sequencing (PIC-seq) is an advanced multiomics technology deciphering the crosstalk between the cellular components of an immunological synapse (Cohen et al., 2022; Giladi et al., 2020). To assess Immediate activation signatures, we applied PIC-seq on a model of B-ALL cell lines (RS4;11, NALM-6) and lymphocytes obtained from healthy subjects, activated by blinatumomab, compared to no-treatment and activation with anti CD3-CD28 antibodies. To examine the Sustained effects on the immune TME, we performed a longitudinal single-cell RNA sequencing of the bone BM of adult B-ALL patients, before and after treatment with blinatumomab in the Division of Hematology in the Tel Aviv Sourasky Medical Center in 2021-22. Results Immediate activation Applying PIC-seq on n=16,543 CD3 and CD19+ cells, we identified the distinct gene expression of ‘blinatumomab-activated lymphocytes’ (Figure 1). Blinatumomab induced cellular synapses composed of specific T lymphocytes subsets along the activation continuum, namely: effector T cells (CCL5, GNLY, NKG7), early IFN-G activation (IRF1, GBP5), activated cytotoxic (Xcl1-2, IFN-G) and proliferating T cells (CD69, CCND2) . ‘Blinatumomab-activated lymphocytes’ were characterized by a unique activation signature: upregulation of cytotoxicity (Xcl1, IFN-G, GNLY), co-stimulation and B-T cells crosstalk (CD40, CD27, TNFRSF18), immune recruitment (CXCL10, CCL4) and antigen-presentation (TNFSF14, ITGB2) pathways. Late synapses also expressed immunoregulatory molecules (TNFAIP8L2). This signature differed from classical anti CD3-CD28 induced activation and is independent of the donor and the target-cell identity. The malignant cells' response varied: RS4;11 cells manifested cellular senescence, while NALM-6 upregulated INFG-induced apoptotic pathways, suggesting indirect killing in the mechanism of action of BiTEs. Data on the introduction of primary B-ALL patients' cells will be presented at the ASH. Sustained effects We profiled >11,000 cells from three patients: Patient 1, 31-year-old (y/o) female, primary refractory B-ALL (50% BM blasts), attaining transient MRD negativity. Patient 2, 71-y/o male, primary refractory Ph+ B-ALL (74% BM blasts) achieving reduction in MRD following first cycle. Patient 3, 71 y/o, Ph+ B-ALL, treated as consolidation therapy, achieving MRD negativity. Blinatumomab induced a dramatic perturbation in the lymphocytic and myeloid compartments of the BM and was highly patient-specific ( Figure 2). The BM lymphocytic compartment prior to initiation of blinatumomab in molecular remission (patient 3) was characterized by active T and Natural Killer cell states, compared to an abundancy of naïve lymphocytes in active disease (patients 1 and 2). There were no signs of T-cell exhaustion pre or post treatment in all patients. Post-treatment, CD8 T-Central Memory cells proliferated in all patients. Patients treated for active disease (patients 2 and 3), had an expansion of the Tregs population post-treatment. In the myeloid compartment, patients with active disease had more non-classical monocytes, known to correlate with poor prognosis. These were replaced by classical monocytes following treatment, in addition to the emergence of a macrophage-precursor population. Data on the BM and peripheral blood dynamics of an additional six patients will be presented at the ASH. Conclusions We present an advanced single cell dissection of blinatumomab-induced target-effector interaction, providing novel insights into the mechanism of action and TME dynamics to guide patient selection and next generation BiTEs. A larger patients' cohort and introduction of patients' cells to the PIC-seq in vitro model will be presented at the ASH.

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
孙夕然发布了新的文献求助10
刚刚
1秒前
酷波er应助别偷我增肌粉采纳,获得10
1秒前
2秒前
yinyue发布了新的文献求助10
2秒前
3秒前
美满的曼寒完成签到,获得积分10
3秒前
hikh发布了新的文献求助10
3秒前
罗静完成签到,获得积分10
5秒前
5秒前
5秒前
6秒前
7秒前
桐桐应助刻苦的如霜采纳,获得10
7秒前
qin希望应助孙夕然采纳,获得10
7秒前
情怀应助孙夕然采纳,获得10
7秒前
121314wld发布了新的文献求助10
8秒前
科研小贩完成签到,获得积分10
8秒前
核桃发布了新的文献求助10
8秒前
8秒前
8秒前
糕糕完成签到,获得积分10
8秒前
zjx完成签到,获得积分10
9秒前
汉堡包应助Chen采纳,获得10
10秒前
10秒前
小二郎应助万业t采纳,获得10
10秒前
11秒前
量子星尘发布了新的文献求助10
11秒前
shihangZhang发布了新的文献求助10
11秒前
11秒前
12秒前
严怜梦发布了新的文献求助10
12秒前
Hello应助迅速的鹤采纳,获得100
12秒前
12秒前
paradox关注了科研通微信公众号
13秒前
鲸落完成签到,获得积分10
13秒前
13秒前
小芭乐发布了新的文献求助10
13秒前
14秒前
啊沙发上发完成签到,获得积分10
14秒前
高分求助中
Picture Books with Same-sex Parented Families: Unintentional Censorship 700
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
Effective Learning and Mental Wellbeing 300
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3974943
求助须知:如何正确求助?哪些是违规求助? 3519467
关于积分的说明 11198482
捐赠科研通 3255728
什么是DOI,文献DOI怎么找? 1797904
邀请新用户注册赠送积分活动 877261
科研通“疑难数据库(出版商)”最低求助积分说明 806224